Preformulation and early phase method development

Separation Science and Technology

Volumn 10, Issue C, 2011, Pages 361-396

  Bynum, Kevin Coleman ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649958746     PISSN: 18771718     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-375680-0.00009-7     Document Type: Book

References (49)

1. Gibson M. Pharmaceutical preformulation and formulation: A practical guide from Candidate Drug Selection to Commercial Dosage Form 2004, Interpharm/CRC press, Boca Raton.
2. Engel G.L., Farid N.A., Faul M.M., Richardson L.A., Winneroski L.L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 2000, 198:239-247.
3. Adeyeye M.C., Brittan H.G. Preformulation in Solid Dosage Form Development 2008, Informa Healthcare USA Inc., Location.
4. Sarfaraz N. Handbook of Bioequivalence Testing 2007, Informa Healthcare USA, Inc, New York.
5. Bhattachar S., Deschenes L., Wesley J. Solubility: It's not just for physical chemists. Drug Discov. Today 2006, 11(21/22).
6. Swarbrick J., Boylan J. Encyclopedia of Pharmaceutical Technology, Vol I 2002, Marcel Dekker Inc., New York. 2nd ed.
7. Avdeef A., Voloboy D., Foreman A. Dissolution and Solubility, Comprehensive Medicinal Chemistry II Vol. 5 2007, Elsevier, Amsterdam.
8. Berger C., Tsinman O., Voloboy D., Lipp D., Stones S., Avdeef A. Technical Note: Miniaturized Intrinsic Dissolution Rate (Mini-IDR™) Measurement of Griseofulvin and Carbamazepine 2007, Dissolution Technologies, Leawood, KS.
9. Giron D. Monitoring polymorphism of drugs, an on-going challenge-Part 1. Am. Pharm. Rev. 2008, 11(1):66, 68-71.
10. Variankaval N., Sheth A. Physical stability of crystal forms-Implications in drug development. Am. Pharmaceut. Rev. 2007, 10:96-101.
11. Qiu Y., Chen Y., Zhang G. Developing Solid Oral Dosage Forms Pharmaceutical Theory & Practice 2009, Academic Press, New York.
12. Chesnut S., Salisbury J. The role of UHPLC in pharmaceutical development. J. Sep. Sci. 2007, 30(8).
13. Kadav A., Vora D. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets. J. Pharm. Biomed. Anal. 2008, 48(1):120-126.
14. Nováková L., Matysová L., Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006, 68(3):908-918.
15. Ali I., Aboul-Enein H., Ghanem A. Enantioselective toxicity and carcinogenesis. Curr. Pharm. Anal. 2005, 1:109-125.
16. He B., Shi Y. Comprehensive chiral HPLC method development for pharmaceutical compounds during late stage development. Am. Pharmaceut. Rev. 2008, 11(1):47-52.
17. Byrn S., Ralph R., Pfeiffer R., Stowell J. Polymorphs, regulations, crystallization, and solid-state chemistry. Am. Pharmaceut. Rev. 2005, 5(3):92-99.
18. Redman-Furey N., Collins W. Thermoanalytical characterization of pharmaceutical materials: Small molecule applications. Am. Pharmaceut. Rev. 2002, 5(3):100-105.
19. Brittain H. X-Ray powder diffraction of pharmaceutical materials. Am. Pharmaceut. Rev. 2002, 5(1):74-80.
20. Offerdahl T., Munson E. Solid-state NMR spectroscopy of pharmaceutical materials. Am. Pharm. Rev. 2004, 7(1):109-112.
21. Lee D., Webb M. Pharmaceutical Analysis 2003, Taylor & Francis Inc., Philadelphia.
22. Huynh-Ba K. Handbook of Stability Testing in Pharmaceutical Development 2008, Springer-Verlag, New York.
23. Shekunov B., Chattopadhyay P., Tong H., Chow A. Particle size analysis in pharmaceutics: Principles, methods and applications. Pharm. Res. 2007, 24(2).
24. Serajuddin A., Thakur A., Ghoshal R., Fakes M., Ranadive S., Morris K., Varia S. Selection of solid dosage form composition through drug-excipient compatibility testing. J. Pharm. Sci. 1999, 88(7):696-704.
25. Guidance to Industry Blend Uniformity Analysis FDA CDER US Oct 1999.
26. Berman J., A J. Planchard "Blend Uniformity and Unit Dose Sampling". Drug Dev. Ind. Pharm. 1995, 21(11):1257-1283.
27. Storme-Paris I., Clarot I., Esposito S., Chaumeil J.C., Nicolas A., Brion F., Rieutord A., Chamina P. Near InfraRed Spectroscopy homogeneity evaluation of complex powder blends in a small-scale pharmaceutical preformulation process, a real-life application. Eur. J. Pharm. Biopharm. 2009, 72:189-198.
28. Ciurczak E.W. Following the progress of a pharmaceutical mixing study via near-infrared spectroscopy. Pharm. Technol. 1991, 15(9):140-145.
29. Lai C., Holt D., Leung J.C., Cooney C.L., Raju G.K., Hansen P. Real time and noninvasive monitoring of dry powder blend homogeneity. AlChE J. 2001, 47(11):2618-2622.
30. Hailey P.A., Doherty P., Tapsell P., Oliver T., Aldridge P.K. J. Pharm. Biomed. Anal. 1996, 14:551-559.
31. Li W., Worosila G.D. Quantitation of active pharmaceutical ingredients and excipients in powder blends using designed multivariate calibration models by near-infrared spectroscopy. Int. J. Pharm. 2005, 295:213-219.
32. Bynum K., Zielinski J., Patel S., Wabuuyele B., LoBrutto R., Vivilecchia R. Blend uniformity: A mass balance approach. Am. Pharm. Rev. 2007, 10(6):16-27.
33. Li W., Johnson M., Bruce R., Ulrich S., Rasmussen H., Worosila G. Mass-balanced blend uniformity analysis of pharmaceutical powders by at-line near-infrared spectroscopy with a fiber-optic probe. Int. J. Pharm. 2006, 326(1-2):182-185.
34. Ahuja S., Dong M. Handbook of Pharmaceutical Analysis by HPLC 2005, Elsevier, San Diego.
35. Dressmann J., Kramer J. Pharmaceutical Dissolution Testing 2005, Taylor & Francis Group, New York.
36. Cho J., Gemperline P., Salt A., Walker D. UV/visible spectral dissolution monitoring by in situ fiberoptic probes. Anal. Chem. 1995, 67(17).
37. Aldridge P., Kostek L. In situ fiberoptic dissolution analysis. Dissolution Technol. 1995, 2(4):10-11.
38. Toher C., Nielsen P., Foreman A., Avdeef A. In situ fiberoptic dissolution monitoring of a vitamin B12 solid dosage formulation. Dissolution Technol. 2003, 10(4).
39. Nir I., Johnson B., Johansson J., Schatz C. Application of fiberoptic dissolution testing for actual products. Pharm. Technol. 2001, 25(5).
40. Zoeller T., Klein S. Simplified biorelevant media for screening dissolution performance of poorly soluble drugs. Dissolution Technol. 2007, 14(4).
41. Grundy J., Anderson K., Rogers J., Fosters R. Studies on dissolution testing of the niefedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test. J. Control. Release 1997, 48:1-8.
42. Grundy J., Anderson K., Rogers J., Fosters R. Studies on dissolution testing of the niefedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test. J. Control. Release 1997, 48:9-17.
43. Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) 1997.
44. USP 32-NF 27 <1092> the Dissolution Procedure: Development and Validation.
45. Lagace M., Gravelle L., Di Maso M., McClintock S. Developing a discriminating dissolution procedure for a dual active pharmaceutical product with unique solubility characteristics. Dissolution Technol. 2004, 11(1).
46. Krishna R., Yu L. Biopharmaceutics Applications in Drug Development 2007, Springer, New York.
47. Hanson R., Gray V. Handbook of Dissolution Testing 2004, Dissolution Technologies, Inc. 3rd ed.
48. 48. ICH Q3B(R2): Impurities in New Drug Products 2006.
49. Bynum K., Roinestad K., Kassis A., Pocreva J., Gehrlein L., Cheng F., Palermo P. Analytical performance of a fiberoptic probe dissolution system. Dissolution Technol. 2001, 8(4).